Effect of a remotely delivered tailored multicomponent approach to enhance medication taking for patients with hyperlipidemia, hypertension, and diabetes: The STIC2IT cluster randomized clinical trial

JAMA Internal Medicine Aug 10, 2018

Choudhry NK, et al. - Researchers investigated if a remotely delivered multicomponent behaviorally tailored intervention improves adherence to medications for hyperlipidemia, hypertension, and diabetes vs usual care. Outcomes of this study suggest a statistically significant increase in medication adherence in association with this remotely delivered multicomponent behaviorally tailored intervention, however, there appeared no change in clinical outcomes.


  • Researchers performed a two-arm pragmatic cluster randomized controlled trial at a multispecialty group practice.
  • Participants were patients (18 to 85 years old) with suboptimal hyperlipidemia, hypertension, or diabetes control, and were not adherent to prescribed medications for these conditions.
  • Participants were provided usual care or a multicomponent intervention using telephone-delivered behavioral interviewing by trained clinical pharmacists, text messaging, pillboxes, and mailed progress reports.
  • Medication adherence from pharmacy claims data was assessed as the primary outcome measure.
  • They assessed disease control based on achieved levels of low-density lipoprotein cholesterol, systolic blood pressure, and hemoglobin A1c via electronic health records, and health care resource use from claims data as secondary outcome measures.
  • Using intention-to-treat principles and multiple imputation for missing values, they evaluated the outcomes.


  • From 14 practice sites, researchers included 4,078 participants (mean (SD) age: 59.8 (11.6) years; 45.1% females).
  • They noted a 4.7% (95% CI, 3.0%-6.4%) improvement in adherence with intervention vs usual care, however, there was no difference in the odds of achieving good disease control for at least 1 (odds ratio [OR], 1.10; 95% CI, 0.94-1.28) or all eligible conditions (OR, 1.05; 95% CI, 0.91-1.22), hospitalization (OR, 1.02; 95% CI, 0.78-1.34), or having a physician office visit (OR, 1.11; 95% CI, 0.91-1.36).
  • Intervention participants displayed significantly less risk for an emergency department visit (OR, 0.62; 95% CI, 0.45-0.85).
  • In as-treated analyses, a 10.4% (95% CI, 8.2%-12.5%) increase in adherence, a significant increase in patients achieving disease control for at least 1 eligible condition (OR, 1.24; 95% CI, 1.03-1.50), and nonsignificantly improved disease control for all eligible conditions was evident in association with the intervention (OR, 1.18; 95% CI, 0.99-1.41).
Go to Original
Non loggedin lock

To read this article Sign up / Login for free

This article is only available to members. Are you a doctor? Click here to signup for free.
M3 app logo
Choose easy access to M3 India from your mobile!

M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen